itacnosertib   Click here for help

GtoPdb Ligand ID: 10632

Synonyms: example 11 [WO2014151871A9] | TP-0184 | TP0184
Compound class: Synthetic organic
Comment: The chemical structure that was submitted to the WHO for the INN itacnosertib is identical to the structure of example 11 that is claimed in Tolero Pharmaceuticals' patent WO2014151871A9 [1]. The INN submission declares itacnosertib as a 'serine/threonine kinase inhibitor'. Data presented in WO2014151871A9 provide evidence of example 11's activity as an inhibitor of the activin A receptor type 1 (ACVR1; a.k.a. ALK2) which is a Type I receptor serine/threonine kinase. Tolero have declared an ACVR1-targeting oncology programme on their pipeline webpage. The research code provided is TP-0184, but to date (Dec 2020) there has been no formal name>structure disclosure for this compound.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 91.33
Molecular weight 468.24
XLogP 3.11
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1cc(ccc1N1CCN(CC1)C)Nc1nccc(n1)Nc1cccnc1c1ccccn1
Isomeric SMILES COc1cc(ccc1N1CCN(CC1)C)Nc1nccc(n1)Nc1cccnc1c1ccccn1
InChI InChI=1S/C26H28N8O/c1-33-14-16-34(17-15-33)22-9-8-19(18-23(22)35-2)30-26-29-13-10-24(32-26)31-21-7-5-12-28-25(21)20-6-3-4-11-27-20/h3-13,18H,14-17H2,1-2H3,(H2,29,30,31,32)
No information available.
Summary of Clinical Use Click here for help
If itacnosertib/example 11 is indeed TP-0184, the compound has been advanced to Phase 1 evaluation as monotherapy in patients with ACVR1 pathway-activated advanced solid tumours. Click here to link to's full list of TP-0184 studies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03429218 First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors Phase 1 Interventional Sumitomo Dainippon Pharma Oncology, Inc
NCT04623996 A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS Phase 1/Phase 2 Interventional Sumitomo Dainippon Pharma Oncology, Inc